Universal nirsevimab slashes RSV infant hospitalizations, study suggests
Giving the long-acting monoclonal antibody nirsevimab to most infants sharply decreased hospitalizations and clinic visits linked to respiratory syncytial virus ...
Giving the long-acting monoclonal antibody nirsevimab to most infants sharply decreased hospitalizations and clinic visits linked to respiratory syncytial virus ...
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also reduce these ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.